Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Kevin Warsh, a leading candidate for Federal Reserve Chair, has historically framed Bitcoin not as a threat but as a crucial policy signal. His past comments labeling it 'the new gold' for younger investors stand in stark contrast to the cryptocurrency's recent 3% decline, highlighting the volatile intersection of regulatory sentiment and digital asset markets.
After a period of Bitcoin dominance, a confluence of technological maturity, shifting institutional narratives, and regulatory clarity could propel Ethereum back into the spotlight. Analysts point to its foundational role in decentralized finance and a series of upcoming catalysts as reasons for a potential breakout year.
Zions Bancorporation has authorized a new $75 million stock repurchase program, a move analysts see as a bet on its undervalued shares and a commitment to shareholder returns as regional banks navigate a cautious regulatory environment.
NVIDIA's CEO Jensen Huang indicates that Chinese regulatory approval for the sale of its flagship H200 AI chip is still pending, amid high demand from major tech firms and ongoing U.S.-China tech tensions.
A South Korean family's paper wealth soared past $800 million after their company, L&F Co., inked a landmark battery materials deal with Tesla. Less than two years later, a quiet regulatory filing slashed the contract's value by 99.9997%, a collapse tied directly to Tesla's production struggles with its Cybertruck and 4680 battery cells.
Ripple has obtained a full Electronic Money Institution (EMI) license from Luxembourg's CSSF, granting it passporting rights across the European Union. This marks a significant regulatory milestone following recent UK approval and a period of aggressive fundraising and acquisitions.
A new breed of online platforms is enabling speculation on housing market trends without the need to buy property, drawing both intrigued investors and sharp regulatory criticism.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
The European Commission has granted regulatory approval, concluding the acquisition of iconic Italian motorsports brand Dainese by asset management firms Arcmont and HPS Investment Partners, effectively placing ownership under major institutional investors.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
The industrial sector has outperformed the broader market, buoyed by regulatory shifts. However, not all companies are equally positioned. We analyze one stock with a durable edge and two facing potential headwinds.
Broadcom secures a pivotal, multi-year agreement to supply custom AI chips to OpenAI, cementing its role as a key silicon partner for tech giants. However, the semiconductor leader must simultaneously navigate customer churn from its VMware unit and heightened regulatory scrutiny, presenting a complex risk-reward profile for investors.
A key ally of Prime Minister Narendra Modi has proposed legislation to prohibit social media access for children under 16, framing the move as a response to digital addiction and the exploitation of Indian user data by foreign tech giants, amid a growing global regulatory push.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
While a routine regulatory filing on voting rights draws little market reaction, analysts are focusing on Heidelberg Materials' pivotal role in the global push for sustainable construction. The company's journey from traditional cement producer to a leader in decarbonized building solutions is fraught with both opportunity and significant financial risk.
Boeing reports a surge in orders and finalizes its Spirit AeroSystems buyout, aiming to solidify its supply chain. However, ongoing production challenges and regulatory scrutiny cast a shadow over its ambitious ramp-up plans.
As SpaceX nears a deal to acquire xAI, analysts see a straightforward step in Elon Musk's grand vision. However, integrating the publicly traded Tesla into a sprawling 'Musk Inc.' conglomerate presents a far more complex financial and regulatory challenge for investors.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
